Danaher (NYSE:DHR) Price Target Cut to $285.00 by Analysts at Citigroup

Danaher (NYSE:DHR) had its target price lowered by stock analysts at Citigroup from $305.00 to $285.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the conglomerate’s stock. Citigroup’s price target would suggest a potential upside of 19.71% from the stock’s previous close.

Several other research analysts have also recently weighed in on DHR. Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Royal Bank of Canada dropped their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Barclays decreased their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Raymond James dropped their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus raised their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Stock Performance

Shares of NYSE:DHR traded up $3.23 on Monday, hitting $238.07. The company had a trading volume of 3,654,613 shares, compared to its average volume of 2,664,542. The stock has a market cap of $171.95 billion, a price-to-earnings ratio of 45.43, a P/E/G ratio of 4.33 and a beta of 0.83. The stock has a 50 day moving average price of $236.37 and a 200 day moving average price of $254.29. Danaher has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm earned $2.02 EPS. The business’s revenue was up 3.1% on a year-over-year basis. Analysts expect that Danaher will post 7.5 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DHR. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at approximately $50,000. Darwin Wealth Management LLC bought a new stake in shares of Danaher during the third quarter valued at approximately $55,000. Finally, Dunhill Financial LLC lifted its holdings in shares of Danaher by 45.1% in the 3rd quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.